Preclinical Studies of Raloxifene and Related Compounds
Author:
Fuchs-Young Robin
Reference85 articles.
1. Jones CD, Suarez T, Massey EH, Black LJ, Tinsley FC. Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)etho xy]-phenyl]methanone, methanesulfonic acid salt. J Med Chem 1979; 22:962–966.
2. Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CW, III, et al. Structure-Activity Relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40:146–167.
3. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997; 94:14105–14110.
4. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molec Endocrinol 1995; 9:659–669.
5. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene. Science 1996; 273:1222–1225.